ArticlePloS one2012
Repression of cardiac hypertrophy by KLF15: underlying mechanisms and therapeutic implications.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Sex-dependent epigenomic and transcriptomic reprogramming links maternal obesity to cardiac remodeling in adult offspring.American journal of physiology. Heart and circulatory physiology · 2026Article
- PEDV envelope protein promotes viral replication by remodeling host iron homeostasis via the TRIM28-KLF15-FPN axis.Journal of virology · 2026Article
- Article
- Glucocorticoid-Mediated Skeletal Muscle Atrophy: Molecular Mechanisms and Potential Therapeutic Targets.International journal of molecular sciences · 2025Review
- Investigation of coagulation and proteomics profiles in symptomatic feline hypertrophic cardiomyopathy and healthy control cats.BMC veterinary research · 2024Article
- CRISPR activation and interference as investigative tools in the cardiovascular system.The international journal of biochemistry & cell biology · 2023Article
- Deep phenotyping of miRNAs in exercise-induced cardiac hypertrophy and fibrosis.Journal of biosciences · 2023Article
- Article
- Role of resveratrol in inhibiting pathological cardiac remodeling.Frontiers in pharmacology · 2022Review
- Expressions and relationship of Krüppel-like factor 15 and endothelial nitric oxide synthase in experimental deep venous thrombosis.Annals of translational medicine · 2020Article
- Transcriptome analysis of Klf15‑mediated inhibitory functions in a mouse deep venous thrombosis model.International journal of molecular medicine · 2020Article
- MiR-125a-3p-KLF15-BCAA Regulates the Skeletal Muscle Branched-Chain Amino Acid Metabolism in Nile Tilapia (Frontiers in genetics · 2020Article
- Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure.Cardiovascular diabetology · 2019Article
- Testosterone deficiency reduces cardiac hypertrophy in a rat model of severe volume overload.Physiological reports · 2019Article
- Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- A mutation in mouse Krüppel-like factor 15 alters the gut microbiome and response to obesogenic diet.PloS one · 2019Article
- Protective effect of KLF15 on vascular endothelial dysfunction induced by TNF‑α.Molecular medicine reports · 2018Article
- Estrogen receptor beta maintains expression of KLF15 to prevent cardiac myocyte hypertrophy in female rodents.Molecular and cellular endocrinology · 2018Article
- Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15.BMC nephrology · 2018Article
- Advances in the relationship between Kruppel-like factor 15 and cardiovascular disease research.Cardiovascular endocrinology & metabolism · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Kruppel-like factor (KLF) family of transcription factors regulates diverse cell biological processes including proliferation, differentiation, survival and growth. Previous studies have shown that KLF15 inhibits cardiac hypertrophy by repressing the activity of pivotal cardiac transcription factors such as GATA4, MEF2 and myocardin. We set out this study to characterize the interaction of KLF15 with putative other transcription factors. We first show that KLF15 interacts with myocardin-related transcription factors (MRTFs) and strongly represses the transcriptional activity of MRTF-A and MRTF-B. Second, we identified a region within the C-terminal zinc fingers of KLF15 that contains the nuclear localization signal. Third, we investigated whether overexpression of KLF15 in the heart would have therapeutic potential. Using recombinant adeno-associated viruses (rAAV) we have overexpressed KLF15 specifically in the mouse heart and provide the first evidence that elevation of cardiac KLF15 levels prevents the development of cardiac hypertrophy in a model of Angiotensin II induced hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.